Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 46Sarcoma 21Neoplasms 18Neoplasm Metastasis 15Ovarian Neoplasms 12Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 8Recurrence 5Melanoma 5Fallopian Tube Neoplasms 5Thyroid Neoplasms 4Prostatic Neoplasms 4Liposarcoma 4Hemangiosarcoma 4Urinary Bladder Neoplasms 3Solid Tumors 3Lung Neoplasms 3Leiomyosarcoma 3Kidney Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Carcinoma, Ovarian Epithelial 3Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Refractory Solid Tumors 2Neuroendocrine Tumors 2Gliosarcoma 2Financial Stress 2Chondrosarcoma, Extraskeletal Myxoid 2

Interventions

sipuleucel-T 1pazopanib 1enzalutamide 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma of the Prostate × pazopanib × Clear all
NCT01832259 2018-12-12

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

University of Utah

Phase 2 Completed
30 enrolled 10 charts
Genitourinary

Adenocarcinoma of the Prostate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡